Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical DLI and IL-2 After Auto-SCT for Advanced Lymphoid Malignancies
NCT00248430Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2003
- Modality
- Cytokines & Interferons, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of therapeutic allogeneic lymphocytes and aldesleukin in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 2 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Feasibility of haploidentical related donor lymphocyte infusions and interleukin-2 and Toxicity of haploidentical related donor lymphocyte infusions and interleukin-2. Started Aug 2003; status: completed.
02
Drugs
therapeutic allogeneic lymphocytesaldesleukin
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00248430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248430.